8-K/A: Alaunos Therapeutics Announces 1-for-10 Reverse Stock Split

Alaunos Therapeutics has finalized a 1-for-10 reverse stock split, effective July 17, 2024, to increase the per-share price of its common stock.

Summary

• Alaunos Therapeutics has completed a 1-for-10 reverse stock split of its common stock.
• The reverse stock split was approved by the Board of Directors on June 26, 2024, and will be effective on July 17, 2024, at 5:00 p.m. Eastern Time.
• Every 10 shares of common stock will be combined into 1 share.
• Trading will begin on a split-adjusted basis on July 18, 2024, under the same ticker symbol, TCRT, but with a new CUSIP number, 98973P309.
• The reverse stock split was authorized by stockholders at the Annual Meeting on June 6, 2024, with the board having discretion to set the ratio between 1-for-5 and 1-for-15.
• Equiniti Trust Company is the exchange agent and will provide instructions to stockholders on exchanging pre-split shares for post-split shares.
• Fractional shares will not be issued; instead, shareholders will receive cash based on the closing price of the stock on the day before the effective time.

Sentiment

Score: 6

Explanation: The document is neutral in tone, detailing a previously approved corporate action. While reverse stock splits can be viewed negatively, this action was expected and is presented factually.

Positives

• The reverse stock split is a step to increase the per-share price of the company's common stock.
• The company has secured an exchange agent to manage the process of exchanging shares.

Risks

• Reverse stock splits can sometimes be perceived negatively by the market.
• The company's stock price may be volatile following the reverse split.

Future Outlook

The company will begin trading on a split-adjusted basis on July 18, 2024.

Management Comments

• The Board of Directors approved the reverse stock split and the 1-for-10 ratio.

Industry Context

Reverse stock splits are a common corporate action for companies seeking to increase their stock price to meet listing requirements or attract institutional investors.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies to avoid delisting from exchanges like Nasdaq, which often have minimum share price requirements.
• The 1-for-10 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.
• Other companies that have recently undertaken reverse stock splits include Cassava Sciences (SAVA) and Faraday Future Intelligent Electric (FFIE), which used a 1-for-10 and 1-for-80 ratio respectively.

Stakeholder Impact

• Shareholders will have fewer shares, but each share will represent a larger portion of the company.
• The reverse stock split may impact the perceived value of the company by investors.

Next Steps

• Stockholders will receive instructions from Equiniti Trust Company on how to exchange their pre-split shares for post-split shares.
• The company will begin trading on a split-adjusted basis on July 18, 2024.

Key Dates

Keywords

reverse stock split, common stock, stock split, TCRT, Alaunos Therapeutics, shareholder, Equiniti Trust Company